Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Esperion Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Led by Roger Newton, PhD, the former head of the atherosclerotic research team at Warner-Lambert's Parke-Davis division that discovered and developed {Lipitor}, Esperion Therapeutics Inc. was founded to exploit the reverse cholesterol transport pathway for the development of a new class of anti-cholesterol drugs, starting with a preclinical candidate licensed from Pharmacia & Upjohn Inc. called ApoA-I Milano.

You may also be interested in...

GSK Puts Up (Another) Venture Fund

The name of GlaxoSmithKline's just-launched, $500 million venture fund--GSK Venture Fund--lacks pizzazz, but might do more for the pharma firm on a broader scale than its precursor, SR One. The new effort, which has yet to be formally announced, takes a more conventional--and maybe more assertive--VC approach to nailing down rights and/or starting product- and technology-focused companies.

Torcetrapib: Biomarker for the Big Pharma Business Model

As biotechs often live or die on the success of one pipeline project, so too Pfizer finds itself in the same position. Weak drug launches, intense competition in its core cholesterol franchise, and, analysts say, an unimpressive pipeline. Except torcetrapib--perhaps the most important clinical-stage project in the industry. If it fails, Pfizer's in trouble. If it succeeds, Pfizer will have proven that giantism isn't antithetical to growth.

Hope Springs Eternal in Biopharma IPO Pricing but Bad Haircuts Continue

While START-UP first noted an industry-wide tendency to overestimate the prices IPO investors were willing to pay in early 2005, IPOs have regularly fallen short of the anticipated price ever since, with few exceptions.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts